Thomas Stankovich, Chief Financial Officer at ReShape Lifesciences Inc. (RSLS), sold 106 shares at $1.47 ($156) on 2023-07-06, disclosed to the SEC on 2023-07-19.
Open-market sale of $156 RSLS by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| RSLS | SELL | 2023-07-06 | $746 | — | Filing → |
| RSLS | BUY | 2023-07-06 | $27K | — | Filing → |
| RSLS | SELL | 2023-03-07 | $4K | — | Filing → |